Clean Science and Technology Ltd. announces a new order win

Kemin Industries Supply Deal Overview

• Supply Deal Scope: Clean Science & Technology Limited entered into a five-year strategic supply agreement with Kemin Industries, effective August 1, 2026, to serve as a primary supplier of key ingredients for the food and feed sector ^[1]. The transaction was disclosed under Regulation 30 of the SEBI Listing Regulations ^[1].
• Capacity & CAPEX Attribution: Specific disclosures detailing whether this supply arrangement utilizes existing unutilized capacity within the FMCG Chemicals segment or requires dedicated incremental CAPEX have not been reported in available company filings.
• Capacity Utilization Rates: Plant-wise and segment-wise capacity utilization rates for the FMCG Chemicals business were not separately disclosed in reported presentation materials.

---

Capital Expenditure & Asset Buildout Indicators

While specific contract-level capacity allocation is not reported, consolidated financial metrics highlight ongoing balance-sheet capital deployment:

---

Analytical Takeaways & Disclosure Gaps

• Subsidiary-Led Capital Outlays: The divergence between consolidated TTM Capex to Revenue (21.0% ^[2]) and standalone TTM Capex to Revenue (2.7% ^[3]), combined with a 290.7% YoY increase in consolidated CWIP ^[4], indicates that primary capacity creation is occurring within subsidiary units (e.g., Clean FNC).
• Revenue Visibility vs. Operational Clarity: The multi-year deal provides multi-year demand visibility in food and feed ingredients ^[1]. However, quantifying its direct impact on asset turnover requires company disclosure on dedicated product lines, volume allocations, and baseline segment utilization.

Strategic Supply Scope

Clean Science and Technology Limited's regulatory disclosures do not specify whether the five-year strategic arrangement with Kemin Industries involves established products from its existing portfolio or a newly commercialized molecule developed from its R&D and pilot pipeline ^[6].

Disclosed Contract Parameters

• Counterparty and Duration: Clean Science signed a long-term strategic supply agreement with Kemin Industries for an initial primary term of five years, effective August 1, 2026 ^[6].
• Product Classification: The filing defines the scope broadly as "key ingredients to support its food and feed industry" operations ^[6].
• Supply Position: Clean Science will act as a substantial primary supplier for Kemin Industries across the contracted period ^[6].
• Omitted Commercial Details: The company has not publicly disclosed specific molecule names, product categories, volumes, pricing terms, capital expenditure commitments, or whether the production utilizes existing operational lines versus newly commercialized pilot-scale capacity ^[6]. Third-party media reports covering the announcement similarly reflect only the broad five-year primary supply framework ^[1].

Analytical Assessment & Implications

• Portfolio Fit: Clean Science's existing product mix includes performance chemicals and specialty ingredients (such as antioxidants like BHA, TBHQ, and Ascorbyl Palmitate) used in food, feed, and animal nutrition applications. Supply into the food and feed sector is structurally aligned with its core chemical competencies.
• Revenue Visibility: Regardless of whether the contract utilizes existing installed capacity or scales up a novel molecule, securing primary supplier status with a global food and feed industry player provides five-year base volume visibility ^[6].
• Key Disclosures to Track: Confirmation on whether this deal monetizes existing unutilized capacity or represents the commercial-scale launch of a newly developed derivative will depend on management commentary in upcoming quarterly earnings calls or investor presentations.

Revenue Mix and Diversification Strategy

Clean Science and Technology's strategy focuses on broadening its revenue base beyond its historical anchor products by expanding capacity in Performance Chemicals, introducing HALS (hindered amine light stabilizers), and scaling FMCG chemical lines such as food-grade antioxidants ^[7].

Reported Segment Revenue Mix (FY26)

For FY26, Clean Science reported standalone revenue of Rs 813.84 Crores ^[8] (disclosed as Rs 815 Crores in operational updates ^[9]). The standalone revenue breakdown across operating segments was:

• Performance Chemicals: 72% ^[9]
• Pharma-Agro Intermediates: 19% ^[9]
• FMCG Chemicals: 9% ^[9]

Performance Chemicals remains the primary earnings engine, maintaining a 72% revenue share ^[9].

Revenue Diversification Initiatives

Management's ongoing diversification efforts within Performance Chemicals and FMCG Chemicals are being executed across several tracks:

• HALS Portfolio Expansion: HALS commercialization is managed through its wholly owned subsidiary, Clean Fino Chem ^[9]. Management targets scaling HALS sales volumes from 1,900 tonnes in FY25 to an aspirational 9,000–10,000 tonnes by FY28/FY29 ^[7]. This scale-up helped group consolidated revenue reach Rs 956.39 Crores in FY26 ^[10] despite standalone revenue headwinds ^[9].
• Performance Chemicals Capex: The company is executing two Rs 150 Crore capex projects in Performance Chemicals ^[7]. The first facility (Performance Chemical 1) adds 10,000 tonnes of installed capacity with an estimated peak revenue potential of ~Rs 300 Crores at full scale ^[7].
• FMCG and Food Antioxidants Expansion: Clean Science expanded capacities in food-grade antioxidants and commercialized new products such as Barbituric acid ^[7], directly addressing FMCG and human/animal nutrition applications.

---

Impact of Kemin Industries Partnership on Customer Concentration

Contract and Concentration Disclosure Status

Specific details regarding a commercial agreement, order volume, or revenue contribution associated with Kemin Industries are not reported in company disclosures or market publications. Quantitative metrics tracking top-5 or top-10 customer concentration profiles following any such engagement are also not separately disclosed.

Strategic Alignment and Implications

• Portfolio Alignment: Off-take or strategic distribution partnerships in food-grade antioxidants or specialty additives align with management's stated strategy to build scale in FMCG Chemicals (currently 9% of standalone revenue ^[9]) and diversify away from single-product dependencies.
• Concentration Impact: Partnering with established global players in nutrition or antioxidants typically provides volume visibility for newly commissioned capacities. However, in the absence of disclosed contract terms or customer concentration percentages, the specific extent to which a partnership with Kemin Industries alters customer concentration or shifts the segment mix cannot be quantified from reported disclosures.